Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 20 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - cloprostenol - solution for injection - 0.250 milligram(s)/millilitre - cloprostenol - cattle - hormone

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Austria - English - HMA (Heads of Medicines Agencies)

virbac s.a. - cloprostenol 87.5 µg/ml - injection - pigs females - cloprostenol

Germany - English - HMA (Heads of Medicines Agencies)

virbac s.a. - cloprostenol 87.5 µg/ml - injection - pigs females - cloprostenol

Spain - English - HMA (Heads of Medicines Agencies)

virbac s.a. - cloprostenol 87.5 µg/ml - injection - pigs females - cloprostenol

France - English - HMA (Heads of Medicines Agencies)

virbac s.a. - cloprostenol 87.5 µg/ml - injection - pigs females - cloprostenol